Salivary gland cancers are represented by a heterogeneous histologic group of tumors, with low incidence, which may appear both in major and minor salivary glands. This article presents a review of the difficulties which may be encountered in this pathology during the treatment. The diagnosis of salivary gland cancers is often delayed, due to the histopathologic and immunohistochemistry results given in different period of times. There can be several difficulties in following the oncologic pre-treatment protocols, in terms of imaging technique, as MRI, useful for disease staging. The treatment of salivary gland cancers is complex, due to the local anatomy and their aggressive potential. Because of their decreased incidence, there are few data that investigate the treatment in the case of these diseases. The current therapy available for the patients with salivary gland cancers is represented by complete surgical resection. Several treatment difficulties in cancers of the salivary glands may come from the surgical limitations and the insufficient data for adjuvant and palliative treatment. Due to the limitations of the local health system, there is a heterogeneous distribution of the oncologic centers, lack of equipment, prolonged time to follow general protocols, despite the aspect of case-individualized therapy according to the guidelines. We must not forget the tumor behaviour and individual reactivity of different patients to the same treatment protocol.
INTRODUCTION
Salivary gland cancers have a relatively low incidence, representing 3-7% of head and neck malignant tumors 1 . Salivary gland tumoral masses may appear inside the major salivary glands (submandibular, sublingual or parotid) or inside the minor salivary glands found submucosally, in the upper aero-digestive pathway 1 . The parotid glands are the most frequently involved, in 64% to 80% of the cases, followed by the submandibular salivary glands (in 7% to 11% of the cases), sublingual glands (1%) and minor salivary glands (9% to 23%). These malignancies tend to appear in the fourth or fifth decade of life, with an increasing incidence with age and especially in men 2 . The etiology of these tumors is mainly unknown. There have been proven correlations between the Epstein Barr virus or Human papilloma virus infections or immune system suppression, like lymphoepithelial carcinomas, medulloblastomas or HIV infections, and salivary gland neoplasms. At the same time, there has not been reported any association between the etiology of this pathology and smoking or drinking [3] [4] [5] . A great role may be played by the exposure to ionizing radiations.
The general classification of salivary gland cancers is made by the World Health Organization recommendations from 2005, which recognizes 24 histopathological types. These tumor types are divided into two categories, related to their aggressive potential and prognosis 6 . High-risk tumors determine early frequent local metastasis to the lymph nodes and to distance, through haematogenous pathways. The intermediate types are mainly represented by adenoid cystic carcinomas, which invade the cranial nerves and disseminate to the base of the brain. Low-grade cancers have a decreased malignancy potential 7, 8 , the most frequent types being the muco-epidermoid carcinomas, with 2.8-15% incidence Center of excellence for research of sensorial and sensitive disorders, study of infecto-inflammatory, tumoral and obstructive aero-digestive pathology (CESITO), ENT&HNS Department, "Sfanta Maria" Clinical Hospital, Bucharest, Romania apy, the histopathologic diagnosis is needed 9 . Through the diagnostic methods, fine needle aspiration cytology (FNAC) is a special technique able to provide histopathological samples, which can help us establish the proper therapeutic plan. Despite the fact that the method has elevated specificity (85%) and sensitivity (86%), it is operator-sensitive and depends to the doctor's experience, because it requires properly trained physicians 10 . Similar to every diagnosis methods, it has several proven advantages, but it is not infallible.
The advantages are mainly represented by the fact that it is a minimally invasive technique, which is well accepted by the patients. The results obtained are able to distinguish neoplastic from non-neoplastic diseases, to identify lymphoma and salivary gland metastasis from skin cancers, so the doctor can decide between a surgical procedure or non-surgical treatment 11, 12 . Moreover, this diagnostic technique can be a useful tool for the specialist to make the surgical planning and provide a proper preoperatory counselling to the patient 11, 12 .
In the current practice, there are some opponents who related that the information provided through the fine needle aspiration does not change the therapeutic plan, which is mainly surgical. Also, in the case of lymphomas, this technique is not always able to establish a diagnosis; it may require several biopsies, which extend the time for diagnosis and treatment, with increased costs 12 . From the anatomical point of view, the parotid glands have the highest rates of inaccuracy, because they tend to have a large tumoral diversity, and it is not always easy to differentiate between these types. Also, some parotid carcinomas appear nonthreatening at cellular level.
In a study conducted by Balakrishnan et al., they observed that FNAC is not reliable in distinguishing between a malignant and a benign salivary gland tumor 12 . Physicians should interpret the results with extreme precaution. The results of their study indicated that 46% of the samples were diagnostic suggestive, whilst 31% of the samples non-diagnostic, 15% of the cases were aspirates errors and 15% of the samples misleading. The specificity of the fine needle aspiration technique in identifying malignancies was 79%, the sensitivity 84%, whilst the method provided a 68% positive predictive value. In case of lymphomas, fine needle aspiration is not specific, inducing diagnostic errors, with subsequent therapeutic failure; in some of the cases, radical parotidectomy might have been avoided 12 
.
In case of failure, FNAC may be replaced with an alternative investigation, ultrasound-guided core biopsy (USCB) used especially for the parotid glands. This technique is performed under local anaesthesia, with 18-20 G needles, and it has a diagnostic sensitivity of 100% 11 . Open biopsies are not usually recommended, because they might have a high risk of seeding the tumoral cells.
Imaging techniques are represented by the ultrasound examination, which is less expensive and highly sensitive, and CT scan, MRI or PET-CT scan 13 .
PET-CT scan is a useful technique for tumoral staging, by identifying locoregional or distant metastasis, as well as for therapeutic follow-up. In most of the cases (69%), the method has specificity for the tumoral nature, benign or malignant, with almost 100% sensitivity for the malignant disease, with 30% rate of false-positive results. Those falsepositive results usually appear in the case of inflammatory modifications, Warthin tumor or pleomorphic adenoma 13, 14 . In a study conducted by Koyuncu et al., the authors performed a retrospective study, in which they compared the CT and MRI results in the identification of salivary gland cancers 15 . The conclusion was that the MRI technique better distinguished intrinsic lesions, compared to the extrinsic ones. Tumoral infiltration was detected equally by the CT scan and MRI, but MRI is three times more expensive than the CT scan. CT scan and MRI technique are equivalent from the morphological point of view, with similar diagnostic potential in parotid gland tumors, but MRI has proven to be better in evaluating perineural spread.
TREATMENT STRATEGIES IN SALIVARY GLAND CANCERS
The therapeutic approach of salivary gland cancers is currently not standardized 16 . It is mainly represented by surgical approach, along with radiotherapy and chemotherapy, depending on the tumor stage, aggressive potential and the patients' option 17 . Complete tumor resection, with negative margins, is considered nowadays the basic treatment for salivary gland cancers. For example, the only therapy in the case of low-grade cancers that involve the superficial lobe of the parotid gland is superficial parotidectomy. In general, for all other localizations, it is indicated to perform a total parotidectomy 18 . Due to the permanent clinical research in this pathology, the therapeutic results for the patients diagnosed with salivary gland cancers have improved in the past years.
In the current management of salivary gland cancers, there are several difficulties which may be encountered during the treatment and they may be represented by surgical approach of the primary site or the lymph nodes or the adjuvant therapy, radiotherapy or chemotherapy 19 ( Table 1) . Most of the patients diagnosed in early stages tend to have surgery as the main therapeutic step, whereas the patients with advanced disease tend to undergo only radiotherapy, or in combination with systemic chemotherapy (Table 1) . Tumor stage, histology, grading, facial nerve paralysis, extra-parotid tumor extension and cervical node involvement are the most important tumor-related predictors of survival 20 .
Radiotherapy
Salivary gland cancers present a high radiosensitivity and irradiation is currently established as a part of the postoperative adjuvant therapy, in patients who are at risk of locoregional tumor recurrence 21, 22 . There are several studies which indicate that regional tumor control is enhanced with the addition of the postoperative irradiation.
The recommended radiation dose for the main tumoral site and local lymph nodes is 60Gy and 56Gy in the case of negative lymph nodes. For the undissected sites, a total dose of 50Gy is used, with a daily fraction of 2Gy 20 . Radiotherapy alone, especially with fast neutron, is the preferred treatment in patients who are not eligible for surgical approach, due to tumor extension or comorbidities. In general, the patients who are treated only with radiotherapy have an unfavourable prognosis. Because of the fact that this pathology has a low incidence, there is a lack of randomized clinical studies for establishing the role of adjuvant radiotherapy 1 . Postoperative radiation therapy (PORT) is recommended in patients with negative prognostic, like T3 or T4 stages, with incomplete or close resection margins, highgrade tumors with perineural spread or vascular invasion; invaded lymph nodes 1 . The role of adjuvant radiotherapy in patients with T1 or T2 stages and complete surgical resection has not been confirmed yet 24 .
Compared with intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT), the new treatment through intensity-modulated proton therapy (IMPT) is able to allow the optimal radiation dose distribution to the tumoral site, which determines a total dose decrease and improves the sparing of healthy tissues, but with similar therapeutic results
24
. Recent studies show that neutron-beam radiation therapy has a higher efficiency compared to conventional radiation in salivary gland cancers, because it is able to reduce the tumoral mass, with less adverse effects upon the surrounding normal tissue 25, 26 . This radiation technique is recommended in the case of advanced or recurrent disease, although it does not improve the survival rate.
Neck dissection
The presence of the cervical lymph node at the moment of diagnosis represents an important prediction factor 1 . In 10-20% of the cases, there are also occult lymph nodes metastases, especially in high-grade cancers.
At the moment of primary surgery, it is recommended to perform also a therapeutic neck dissection in patients with clinically positive lymph nodes. Postoperative radiotherapy must be applied in these cases, regardless of the histological tumor type 24 . In the case of clinical negative lymph nodes, N0, the treatment is still controversial and it may consist in elective neck dissection, observation or prophylactic radiation. The studies recommend that elective neck dissection should be performed for high-grade tumor types 1 . Valstar et al. performed a metanalysis in order to determine the usefulness of the elective neck dissection in patients with clinically negative lymph nodes 26 . The study consisted in reviewing 39 papers for a period of ten years, between 1997 and 2007. The results of their metanalysis indicated that 83% of the patients, from a total number of 871 patients, were considered N0 using clinical (palpation) and imaging assessment. The histopathology from elective neck dissection identified occult metastases in 23% of the patients. Local tumoral recurrence appeared in approximately 5% of the cases, after aggressive approach. In terms of facial nerve involvement, nerve sacrifice has proven a great local disease control, but with the disadvantage of poor quality of life. Postoperative radiotherapy improved local control rates in the patients included in the study.
The aggressiveness of the disease may be quantified using several prognostic factors, such as high-grade tumor type, facial nerve involvement, age higher than 54 years old, perilymphatic spread, stages T3 or T4 of the disease. In the presence of negative predictive factors, neck dissection must be performed in addition to local surgery 27, 28 .
Chemotherapy
In the case of localized disease, the therapeutic approach consists in surgery alone or associated with postoperative radiotherapy, whilst in the case of recurrent or advanced disease, systemic therapy is preferred. There are few things clearly described in the chemotherapy for salivary gland cancers, due to its low incidence. The patients with local recurrence or distant metastasis still represent a challenge, in order to identify the proper therapeutic approach. Currently, there is no consensus either to perform surgery alone, radiotherapy alone or both therapy types combined 1, 28 . Salivary gland cancers are considered to be chemotherapy-resistant, but almost half of these patients will still experience tumoral shrinkage. Usually, salivary gland cancers are associated with local relapsing and metastasis and systemic therapy does not provide satisfactory results. Conventional chemotherapy substances (cisplatin, 5-FU and cyclophosphamide) are considered the firstline chemotherapics for the patients with advanced disease. Some studies showed that the survival rates for the patients with distant metastasis were similar, regardless of chemotherapy (35.2% vs. 27.6%, P = 0.747) 1 . In order to improve the patients' outcome and prognosis, there is an urgent need to perform future clinical studies, to identify new molecules or therapeutic agents. The study of the epidermal growth factor -EGF receptor family (EGFR and HER2) and androgen receptors seems like a promising option in the future, due to their overexpression in this pathology 29 . EGFR blockage with Cetuximab and Erlotinib is considered to inhibit tumoral growth. Other molecules, like Bevacizumab and Vanitib, are proposed in the treatment of this pathology, due to their ability to inhibit the vascular endothelial growth factors (VEGF), with a secondary inhibition of the tumoral angiogenesis.
TREATMENT DIFFICULTIES
The treatment difficulties with which we can confront in the salivary gland neoplasm arise from the surgery technique or the health system.
Surgery difficulties
In order to improve the therapeutic outcome, the type of surgery must be considered, either functional or radical, taking into consideration the patients' comorbidities and expectancy, along with tumor characteristics. It is difficult to decide how much functional surgery may be performed, in order to be oncologically correct 1, 30 . Regarding the surgical therapy, there are several difficulties that might be encountered, especially in parotid gland cancers, due to the facial nerve involvement (Figure 1) . Intraoperative facial nerve monitoring is recommended to be used, in order to try to decrease the post- operative associated facial nerve paralysis. In the case of facial nerve tumoral involvement, sacrifice is the mainstay, with a nerve repair that can be done during the same surgical procedure. In locally advanced diseases, with tumor extension at vital vascular or neural structures (the mandible, the cervical spine), the surgical approach is difficult. Positive N3 neck lymph node is difficult to surgically manage.
In many cases, local reconstruction is needed for the facial nerve, the remaining skin defects or mandible 31 . In some cases, it is possible for the imaging (CT or MRI) to not fit with the local examination and intraoperative findings (Figure 2, Figure 3 and Figure 4 ). These discrepancies can make the surgical treatment of salivary gland tumors difficult in the light of the chosen surgical technique and patient counselling. 
Health system difficulties
In the current practice, there is a lack of a multidisciplinary head and neck center, which determines the limitation of the complex surgical procedures and the team work. In many departments, the absence of the oncology board does not allow a proper therapeutic planning and follow-up.
The diagnosis of salivary gland cancers is often delayed due to the histopathologic and immunohistochemistry results given in different periods of times. In practice, there are difficulties in following the oncologic pre-treatment protocols, in terms of imaging technique, as MRI, useful for disease staging. Also, some of the physicians tend to ignore the therapeutic guidelines, establishing improper and unrealistic indications.
Once the therapeutic plan is established based on the patients' investigations results, appointments for radiotherapy usually delay the non-surgical treatments. The heterogeneous instrumentation and technologies in different departments do not allow the patients to have a realistic view of the disease.
Treatment difficulties in cancers of the salivary glands come from the heterogeneous distribution of the oncologic centers, lack of equipments, prolonged time to follow general protocols, despite the aspect of case-individualized therapy according to the guidelines. We must not forget the tumor behaviour and individual reactivity of different patients to the same treatment protocol.
We must not forget that patients who are diagnosed with salivary gland cancers have a high risk of developing secondary cancers, especially in other salivary glands, in the oral cavity, the thyroid, the lungs or the kidneys 32 . The main cause for therapeutic failure is local recurrence, cervical lymph nodes metastasis and distant metastasis. This risk depends on the tumoral stage and grade, presence of positive lymph nodes, facial nerve involvement and extraparenchymal extension 33 . Most of the recurrences appear in the first three years, which means this is the critical period when patients must be followed up strictly.
CONCLUSIONS
Salivary gland cancers are a heterogeneous group of neoplasms, with a relatively decreased incidence, but they present a large variety, in terms of histological types. The diagnosis must be established rapidly, through clinical and paraclinical investigations. FNAC is considered an important diagnostic tool, with high sensitivity and specificity, but CT scan and MRI should also be taken into consideration for the therapeutic planning.
The treatment of salivary gland cancers is complex, due to the local anatomy and their aggressive potential. Because of their low incidence, there are few data investigating their management, aspect which arises in several difficulties that we may encounter during the treatment, difficulties that we have presented above. The current therapy available for the patients with salivary gland cancers is represented by complete surgical resection, with negative margins. Also, therapeutic neck dissection must be performed in patients with clinically or imaging positive lymph nodes.
Postoperative radiation therapy is able to improve therapeutic outcomes, especially in high-grade cancers, with positive margins, large tumors and histologic positive lymph nodes.
In patients with advanced inoperable cancers or who refuse the surgical approach, radiotherapy may be taken into consideration. Chemotherapy continues to be used as a palliation in the current therapeutic practice of salivary gland tumors, but constant research is trying to find a curative role as well, in order to improve the outcomes.
